26 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Le, Radiation Oncologist in Stanford, CA?
Castle Connolly Top Doctor
Castle Connolly Top Doctors are doctor-nominated and selected by a physician-led research team.
What are Areas of Expertise for Dr. Le?
Dr. Quynh-Thu Le, MD is a highly-rated, board-certified Radiation Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Le empowers patients to confidently navigate their health journey, specializing in Clinical Trials, Head & Neck Cancer, Lung Cancer, Thoracic Cancers, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Le is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Le go to medical school and complete their residency?
Residency: Univ Ca Sf Sch Of Med, Radiation Oncology; Alameda Co Med Ctr, Flexible Or Transitional Year | UCSF Medical Center | University of California, San Francisco
Medical School: University of Ca, San Francisco, Sch of Med, San Francisco Ca | University of California
Is Dr. Le board certified as a Radiation Oncologist?
Yes, Dr. Quynh-Thu Le, MD is board certified by the American Board of Radiology , American Board of Radiology since 1998
What languages does Dr. Le speak?
Dr. Le and their clinical team can communicate with patients in the following languages:
- English
- Vietnamese
What conditions does a Radiation Oncologist like Dr. Le typically treat?
As a Radiation Oncologist, Dr. Le diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Le. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Throat Cancer
- Oral Cancer
- Tonsil Cancer
- Oropharyngeal Cancer
- Malignant Neoplasm of Tonsil
- Nasopharyngeal Cancer
- Malignant Neoplasm of Nasopharynx
- Pharyngeal Cancer
- Malignant Neoplasm of Oropharynx
ICD-10 Codes:
- C099: Malignant neoplasm of tonsil, unspecified
- C119: Malignant neoplasm of nasopharynx, unspecified
- C109: Malignant neoplasm of oropharynx, unspecified
Also known as:
- Secondary Cancer in Head and Neck Lymph Nodes
- Cancer
- Metastatic Cancer to Neck Lymph Nodes
- Head and Neck Lymph Node Cancer Spread
- Lymph Node Metastasis in Neck
ICD-10 Codes:
- C770: Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
Also known as:
- Oral Cancer
- Mouth Cancer
- Tongue Cancer
- Oral Cavity Cancer
- Tongue Carcinoma
ICD-10 Codes:
- C01: Malignant neoplasm of base of tongue
What procedures does a Radiation Oncologist like Dr. Le typically perform?
As a Radiation Oncologist, Dr. Le performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Le. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Flexible Diagnostic Laryngoscopy
- Voice Box Exam
- Flexible Laryngoscope
- Throat Scope
- Diagnostic Throat Exam
CPT Codes:
- 31575: Laryngoscopy, flexible; diagnostic
Also known as:
- Swallowing Therapy
- Dysphagia Treatment
- Feeding Therapy
- Oral Function Therapy
CPT Codes:
- 92526: Treatment of swallowing dysfunction and/or oral function for feeding
Also known as:
- Flexible Endoscopic Swallowing Evaluation (FEES)
- Swallowing Study (Videofluoroscopy)
- Endoscopy
- Dysphagia Tests
- FEES Test
- Swallowing Endoscopy
- Video Swallowing Study
- Dysphagia Endoscopy
- Videofluoroscopic Swallowing Study (VFSS)
- Modified Barium Swallow (MBS)
- Dysphagia Evaluation
CPT Codes:
- 92612: Flexible endoscopic evaluation of swallowing by cine or video recording;
- 92611: Motion fluoroscopic evaluation of swallowing function by cine or video recording
Does Dr. Le accept my insurance?
Dr. Le accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Le accept in Stanford, CA?
Dr. Le in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Federal government of the United States
Medicare
Santa Cruz County
State of California
UMR Administered Payer
UnitedHealth Group
Valley Health Plan
View All Insurances
Where is Dr. Le's office located?
What hospitals are Dr. Le affiliated with?
Castle Connolly Top Hospital
This doctor is affiliated with a Castle Connolly Top Hospital.
Dr. Le has admitting privileges at the following hospitals:
Recognitions
Publications
Radiotherapy for nodenoid cystic carcinomas of major salivary glands., 2013
A novel aldehyde dehydrogese-3 activator, 2013
Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma., 2013
Cost-effectiveness l, 2013
Stereotactic radiosurgery for retreatment of gross perineural invasion, 2013
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy., 2013
An intertiol collaboration to harmonize the quantitative plasma Epstein, 2013
Migration of implanted markers for image-guided lung tumor stereotactic ablative radiotherapy., 2013
CD44+cells have cancer stem cell-like properties in sopharyngeal carcinoma, 2012
Stereotactic Ablative Radiotherapy for Reirradiation of Locally Recurrent Lung Tumors, 2012
Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors, 2012
Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images, 2012
Evaluation of ProExC as a Prognostic Marker in Oropharyngeal Squamous Cell Carcinomas, 2012
Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer, 2012
Prognostic Value of Metabolic Tumor Volume and Velocity in Predicting Head-and-Neck Cancer Outcomes, 2012
A Planned Neck Dissection Is Not Necessary in All Patients With N2-3 Head-, 2012
Intensity-Modulated Radiotherapy for Tumors of the sal Cavity and Parasal Sinuses, 2012
Quantitation of Human Papillomavirus D in Plasma of Oropharyngeal Carcinoma Patients, 2012
Addition of bevacizumab to st, 2012
Prognostic Significance of Plasma Osteopontin in Patients with Locoregiolly Advanced Head, 2012
Salvage Treatment for Locally Recurrent sopharyngeal Carcinoma (NPC).
A Novel Aldehyde Dehydrogese-3 Activator Leads to Adult Salivary Stem Cell Enrichment In Vivo, 2011
ON-BOARD IMAGING VALIDATION OF OPTICALLY GUIDED STEREOTACTIC RADIOSURGERY POSITIONING SYSTEM FOR, 2011
HIGH RETENTION AND SAFETY OF PERCUTANEOUSLY IMPLANTED ENDOVASCULAR EMBOLIZATION COILS AS FIDUCIAL, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR ORAL CAVITY SQUAMOUS CELL CARCINOMA, 2011
Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head, 2011
POSTRADIATION METABOLIC TUMOR VOLUME PREDICTS OUTCOME IN HEAD-AND-NECK CANCER, 2011
Tumor Volume as a Potential Imaging-Based Risk, 2011
Glioma-Associated Oncogene Family Zinc Finger 1 Expression and Metastasis in Patients With Head and, 2011
MYB Expression and Translocation, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX, 2011
HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETMESE AMERICAN MEN IN CALIFORNIA, 2010
Dose reconstruction for volumetric modulated arc therapy, 2010
The Tumor Microenvironment in Non-Small-Cell Lung Cancer, 2010
MiR-210-micromager of the hypoxia pathway, 2010
Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer, 2010
INTENSITY-MODULATED RADIOTHERAPY IN THE TREATMENT OF OROPHARYNGEAL CANCER, 2010
Identification of a biomarker panel using a multiplex proximity ligation, 2009
COMPARISON OF TREATMENT RESULTS BETWEEN ADULT AND JUVENILE SOPHARYNGEAL CARCINOMA, 2009
Mucositis-Related Morbidity and Resource Utilization in Head and Neck Cancer Patients Receiving, 2009
Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival, 2009
METABOLIC TUMOR VOLUME PREDICTS FOR RECURRENCE AND DEATH IN HEAD-AND-NECK CANCER, 2009
PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models, 2009
THE RELATIONSHIP BETWEEN HUMAN PAPILLOMAVIRUS STATUS AND OTHER MOLECULAR PROGNOSTIC MARKERS IN HEAD, 2009
XBP-1 regulates angiogenesis in human pancreatic adenocarcinomas, 2009
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas., 2009
Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas, 2009
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small, 2008
In vivo H-1 magnetic resonce spectroscopy of lactate in patients with Stage IV head, 2008
Excellent local control with stereotactic radiotherapy boost after exterl beam radiotherapy, 2008
LIC-based on-board imaging feasibility and the dosimetric consequences of head roll in, 2008
Retrospective IMRT dose reconstruction based on cone-beam CT and MLC log-file, 2008
Quantification of motion of different thoracic locations using four-dimensiol computed tomography, 2007
Metabolic tumor burden predicts for disease progression and death in lung cancer, 2007
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and, 2007
Longitudil evaluation of the oral mucositis weekly questionire-head and neck cancer, 2007
Evaluation of patterns of failure, 2007
Identifying and targeting hypoxia in head and neck cancer: A brief overview of current approaches, 2007
sopharyngeal and oropharyngeal carcinomas, 2007
Clinical role of F-18-FDG PET, 2007
Plasma osteopontin is an independent prognostic marker for head and neck cancers, 2006
Results of a phase I dose-escalation study using single, 2006
Indirect MR lymphangiography of the head and neck using conventiol gadolinium contrast, 2006
A multidiscipliry approach to magement in a patient with bilateral superior sulcus non-small, 2006
Advanced-staged tonsillar squamous carcinoma, 2006
Connective tissue growth factor, 2006
Lysyl oxidase is essential for hypoxia-induced metastasis, 2006
An evaluation of tumor oxygetion, 2006
Galectin-1: A link between tumor hypoxia and tumor immune privilege, 2005
Identification of mitogen, 2005
Phase II study to assess the efficacy of conventiolly fractioted radiotherapy followed by a, 2005
A comparison study of different PCR assays in measuring circulating plasma Epstein, 2005
A noninvasive approach for assessing tumor hypoxia in xenografts, 2005
Phase II double-blind r, 2004
Long-Term Outcomes of Surgery Followed by Radiation Therapy for Minor Salivary Gland Carcinomas, 2013
Clinical impact of dose overestimation by effective path length calculation, 2013
Radiotherapy for nonadenoid cystic carcinomas of major salivary glands., 2013
A novel aldehyde dehydrogenase-3 activator, 2013
Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma., 2013
Cost-effectiveness l, 2013
Stereotactic radiosurgery for retreatment of gross perineural invasion, 2013
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy., 2013
An international collaboration to harmonize the quantitative plasma Epstein, 2013
Impact of positron emission tomography, 2013
Volumetric-Modulated Arc Radiotherapy for Skull-Base and Non-Skull-Base Head and Neck Cancer, 2013
Migration of implanted markers for image-guided lung tumor stereotactic ablative radiotherapy., 2013
Loss of the p53/p63 target PERP, 2013
Metabolic imaging metrics correlate with survival, 2012
CD44+cells have cancer stem cell-like properties in nasopharyngeal carcinoma, 2012
Esophageal tolerance to high-dose stereotactic ablative radiotherapy, 2012
Stereotactic Ablative Radiotherapy for Reirradiation of Locally Recurrent Lung Tumors, 2012
Tumor Volume-Adapted Dosing in Stereotactic Ablative Radiotherapy of Lung Tumors, 2012
Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images, 2012
Evaluation of ProExC as a Prognostic Marker in Oropharyngeal Squamous Cell Carcinomas, 2012
Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer, 2012
Prognostic Value of Metabolic Tumor Volume and Velocity in Predicting Head-and-Neck Cancer Outcomes, 2012
A Planned Neck Dissection Is Not Necessary in All Patients With N2-3 Head-, 2012
Intensity-Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses, 2012
Prognostic and Predictive Significance of Plasma HGF and IL, 2012
Quantitation of Human Papillomavirus DNA in Plasma of Oropharyngeal Carcinoma Patients, 2012
Addition of bevacizumab to st, 2012
Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head, 2012
Salvage Treatment for Locally Recurrent Nasopharyngeal Carcinoma (NPC).
Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non, 2012
A Novel Aldehyde Dehydrogenase-3 Activator Leads to Adult Salivary Stem Cell Enrichment In Vivo, 2011
Correlation between metabolic tumor volume, 2011
ON-BOARD IMAGING VALIDATION OF OPTICALLY GUIDED STEREOTACTIC RADIOSURGERY POSITIONING SYSTEM FOR, 2011
HIGH RETENTION AND SAFETY OF PERCUTANEOUSLY IMPLANTED ENDOVASCULAR EMBOLIZATION COILS AS FIDUCIAL, 2011
Results from a Single Institution Ph, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR ORAL CAVITY SQUAMOUS CELL CARCINOMA, 2011
Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head, 2011
Tumor Galectin-1 Mediates Tumor Growth and Metastasis through Regulation of T-Cell Apoptosis, 2011
POSTRADIATION METABOLIC TUMOR VOLUME PREDICTS OUTCOME IN HEAD-AND-NECK CANCER, 2011
Head and Neck Cancer, 2011
Tumor Volume as a Potential Imaging-Based Risk, 2011
Glioma-Associated Oncogene Family Zinc Finger 1 Expression and Metastasis in Patients With Head and, 2011
MYB Expression and Translocation, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX, 2011
Intensity-Modulated and Image-Guided Radiation Therapy for Head and Neck Cancers, 2011
HIGHER INCIDENCE OF HEAD AND NECK CANCERS AMONG VIETNAMESE AMERICAN MEN IN CALIFORNIA, 2010
Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics, 2010
Prognostic Significance of p16, 2010
Dose reconstruction for volumetric modulated arc therapy, 2010
The Tumor Microenvironment in Non-Small-Cell Lung Cancer, 2010
MiR-210-micromanager of the hypoxia pathway, 2010
Image-based modeling of tumor shrinkage in head and neck radiation therapy, 2010
Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer, 2010
Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma, 2010
INTENSITY-MODULATED RADIOTHERAPY IN THE TREATMENT OF OROPHARYNGEAL CANCER, 2010
The RGD Domain of Human Osteopontin Promotes Tumor Growth, 2010
Imaging the Unfolded Protein Response, 2010
Identification of a biomarker panel using a multiplex proximity ligation, 2009
COMPARISON OF TREATMENT RESULTS BETWEEN ADULT AND JUVENILE NASOPHARYNGEAL CARCINOMA, 2009
Mucositis-Related Morbidity and Resource Utilization in Head and Neck Cancer Patients Receiving, 2009
Hypoxia-Inducible mir-210 Regulates Normoxic Gene Expression Involved in Tumor Initiation, 2009
Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival, 2009
METABOLIC TUMOR VOLUME PREDICTS FOR RECURRENCE AND DEATH IN HEAD-AND-NECK CANCER, 2009
PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models, 2009
THE RELATIONSHIP BETWEEN HUMAN PAPILLOMAVIRUS STATUS AND OTHER MOLECULAR PROGNOSTIC MARKERS, 2009
XBP-1 regulates angiogenesis in human pancreatic adenocarcinomas, 2009
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas., 2009
Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the, 2009
Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas, 2009
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small, 2008
Clinical biomarkers for hypoxia targeting, 2008
In vivo H-1 magnetic resonance spectroscopy of lactate in patients with Stage IV head, 2008
Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy, 2008
Molecular Imaging of Hypoxia-Inducible Factor 1 alpha and von Hippel-Lindau Interaction in Mice, 2008
LINAC-based on-board imaging feasibility and the dosimetric consequences of head roll in, 2008
Retrospective IMRT dose reconstruction based on cone-beam CT and MLC log-file, 2008
Quantification of motion of different thoracic locations using four-dimensional computed tomography, 2007
Metabolic tumor burden predicts for disease progression and death in lung cancer, 2007
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and, 2007
Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, 2007
Evaluation of patterns of failure, 2007
Identifying and targeting hypoxia in head and neck cancer: A brief overview of current approaches, 2007
Nasopharyngeal and oropharyngeal carcinomas, 2007
Clinical role of F-18-FDG PET, 2007
Plasma osteopontin is an independent prognostic marker for head and neck cancers, 2006
Results of a phase I dose-escalation study using single, 2006
Indirect MR lymphangiography of the head and neck using conventional gadolinium contrast, 2006
A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small, 2006
Advanced-staged tonsillar squamous carcinoma, 2006
Lung cancer in women: Exploring sex differences in susceptibility, biology, 2006
Connective tissue growth factor, 2006
Mature results from a randomized phase II trial of cisplatin plus 5, 2006
Lysyl oxidase is essential for hypoxia-induced metastasis, 2006
An evaluation of tumor oxygenation, 2006
Comment on: Osteopontin as toxic marker, 2006
Galectin-1: A link between tumor hypoxia and tumor immune privilege, 2005
Identification of mitogen, 2005
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a, 2005
Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a ras-activated enhancer, 2005
A comparison study of different PCR assays in measuring circulating plasma Epstein, 2005
A noninvasive approach for assessing tumor hypoxia in xenografts, 2005
Nonsurgical therapy for stages I and II non-small cell lung cancer, 2005
Positron-emission tomography for surveillance of head and neck cancer, 2005
Long-term results of 100 consecutive comprehensive neck dissections, 2004
Sample classification from protein mass spectrometry, by 'peak probability contrasts', 2004
Identification of hypoxia, 2004
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth, 2004
Phase II double-blind r, 2004
Phase I study of tirapazamine plus cisplatin, 2004
Hypoxic gene expression and metastasis, 2004
The use of plasma surface-enhanced laser desorption
What is Dr. Le's NPI number?A National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Le's National Provider Identifier (NPI) number is 1316002116.
What common questions do patients ask about Dr. Le?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Le